NASDAQ •
Healthcare •
Medical Devices •
Quote as of 05/05/2026 16:00
Company Profile
IndustryMedical Devices
SectorHealthcare
ExchangeNASDAQ
Market Capitalization375.26 mln
Float28.78 mln
Earnings Date05/07/2026
EPS
0.07
Overpriced
P / E
165
Highly speculative
Piotroski F-Score
7
/ 9
Strong
Relative Strength
80
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
Pre-Tax Margin
0.77%
Break-even
Business Description
Delcath Systems is a medical company founded in 1988 and based in Queensbury, New York, that develops tools to fight liver cancer in both the United States and Europe. Its main product, sold as HEPZATO KIT in the US and CHEMOSAT in Europe, delivers powerful chemotherapy directly to the liver while limiting the harmful effects that typically spread through the rest of the body. The company is currently running a clinical trial called FOCUS to study how well this approach works in patients with a form of eye cancer that has spread to the liver.
